Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 9/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804408 | 0.99 | PLA2G4A (0.46) | NR4A2PLA2G4ACNR2LMNAMEN1 | |
| SCHEMBL2807415 | 0.94 | NR4A2 (0.46) | NR4A2PLA2G4ALMNAMEN1KMT2A | |
| SCHEMBL6873834 | 0.85 | LMNA (0.47) | NR4A2PLA2G4ALMNAMEN1KMT2A | |
| SCHEMBL8529581 | 0.77 | CPT1A (0.49) | KDM4E | |
| SCHEMBL13132299 | 0.77 | NR4A2 (0.49) | NR4A2CNR2LMNAMEN1KMT2A | |
| SCHEMBL2810904 | 0.76 | NR4A2 (0.54) | NR4A2PLA2G4ALMNAMEN1KMT2A | |
| SCHEMBL3931725 | 0.76 | KDM4E (0.50) | NR4A2PLA2G4AMEN1KMT2AKDM4E | |
| SCHEMBL8555545 | 0.76 | KDM4E (0.46) | LMNAMEN1KMT2AKDM4E | |
| SCHEMBL8557877 | 0.75 | ABCG2 (0.49) | — | |
| SCHEMBL28440147 | 0.74 | PDE4B (0.56) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | WESTFALISCHE WILHELMS UNIVERSITÄT MÜNSTER (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-2215059-A2 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | Westfälische Wilhelms-Universität Münster (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009040314-A2 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | Westfälische Wilhelms Universität Münster (DE) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | PLD2, PLA2G1B, PLA2G4A | NR4A2 2170/4885PLA2G4A 3/4885CNR2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.